The Tokai journal of experimental and clinical medicine · 2026
Treatment Outcomes of Durvalumab Combination Therapy in Patients with Biliary Tract Cancer.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ito Hiroyuki, Kojima Seiichiro, Tazawa Yousuke, Omura Yuji, Yamaguchi Toru, Cho Tsubomi, Yoshihara Shihou, Nagata Junko, Hirose Shunji, Ogasawara Toshihito, Izumi Hideki, Kaneko Junichi, Suzuki Takayoshi
Аннотация
OBJECTIVES: This study aimed to evaluate the efficacy and safety of gemcitabine, cisplatin, and durvalumab (GCD) combination therapy in patients with biliary tract cancer treated at our hospital.
METHODS: Nineteen patients diagnosed with biliary tract cancer and treated with durvalumab combination therapy at Tokai University Hachioji Hospital between February 1, 2023, and May 31, 2024, were included in this retrospective study.
RESULTS: The median overall survival was 13.7 months, and the median progression-free survival was 7.3 months, comparable to outcomes reported in the TOPAZ-1 trial.
CONCLUSION: GCD therapy demonstrated efficacy and safety similar to those observed in the TOPAZ-1 trial.
METHODS: Nineteen patients diagnosed with biliary tract cancer and treated with durvalumab combination therapy at Tokai University Hachioji Hospital between February 1, 2023, and May 31, 2024, were included in this retrospective study.
RESULTS: The median overall survival was 13.7 months, and the median progression-free survival was 7.3 months, comparable to outcomes reported in the TOPAZ-1 trial.
CONCLUSION: GCD therapy demonstrated efficacy and safety similar to those observed in the TOPAZ-1 trial.